IDA Business & Technology Park, Parkmore West, Galway . Ireland
+ 353 87 434 3893
Metabolomics Products & services
based on proprietary Metabolomic platform patented protocols and products:
the only non-invasive
first CE-marked in-vitro blood-based
diagnostic for NASH (non-alcoholic steatohepatitis or liver inflammation with fibrosis).
OWLiver Care® discriminates healthy from fatty liver; only for Pharma
companies use. Other products in the pipeline.
OWL offers spercialised
metabolomic services to Pharma
companies in the areas of biomarker discovery, clinical studies, companion diagnostics and toxicology.
OWLiver® is non-invasive, more affordable than the other reliable competing technologies (biopsy, MRI), it is scalable, uses standard lab platform, does not depend on human operator’s interpretation or expertise.
3,6 M liver biopsies are prescribed annually in the US and EU for NASH. With a cost of 180€, OWLiver® would represent a 650 M€ immediate opportunity.
US, MX, CA granted, extending to WO
Tested in humans?
clinical validation done
in process, expected for 2021
Exp. December 2021
Spain; others in process
Spain and Mexico
USA exp. 2Q-2019 through a CLIA lab
links of interest